Richmond, VA / ACCESSWIRE / October 14, 2014 / ALR Technologies Inc. (OTC: ALRT) has signed an agreement to launch a clinical outcomes study in Chile as a potential solution to the growing number of diabetic patients in Latin America. ALRT's Health-e-Connect is the only off-the-shelf, FDA-cleared system to allow diabetic patients to remotely connect with physicians through a secure website, where Diabetes Care Facilitators (DCFs) regularly monitor the patients' data looking for readings outside of specified parameters.The upcoming trial follows ALRT's first large-scale commercial deployment of the Health-e-Connect system in the United States through the Kansas City Metropolitan Physicians Association in September. The Latin America trial will treat 100 diabetic patients in Santiago, Chile, with a successful trial expected to help establish a presence for ALRT in the large Latin American market.
"Our system is relatively inexpensive, and with Latin America traditionally not spending quite as much in health care per patient as the US, our system is ideal for there Latin American market and this trial will be the way to prove it," says ALRT President Bill Smith on the "Good Life Revolution" with Jesse Dylan this week, powered by Megacast.
The trial will take two groups of 100 patients each at the Hospital Clinico Metropolitano de la Florida, one of Chile's largest hospitals. The first group will be put on ALRT's Remote Monitoring System with DCFs intervening when adverse trends are identified in a patient's blood glucose levels. The second group of 100 patients will record their blood glucose levels through standard traditional practices by manually logging their own data. ALRT will compare the results at the end of the 6-month trial period. The trial's primary goal will be to decrease patient A1c levels, the measure of average levels of blood glucose over the prior three months regarded as the gold standard in diabetes management. A reduction in A1c reduces the risk of potentially deadly complications of diabetes.A successful trial would reduce average patient A1c levels below 8 percent, the benchmark point for diabetes control.
"Chile has a lot of patients with uncontrolled blood glucose, so if we can prove that our system can get large numbers of patients below 8%, that will get a lot of attention with public health authorities not just in Chile, but in Latin America,"adds ALRT President Bill Smith.
The results of the test will be available on ALRT's website with an eye towards publishing the data in an academic journal in the United States.
In the United States, the federal Medicare program is considering a proposal to reimburse physicians for this type of remote monitoring.In its annual physician payment update for 2015, the Centers for Medicare and Medicaid Services (CMS) proposed to pay physicians for "Chronic Care Management" which would pave the way for remote monitoring technologies like ALRT's Health-e-Connect system to treat Medicare patients with chronic diseases.CMS will make this potentially watershed decision on November 1 and, if decided favorably, reimbursement would flow on January 1, 2015.
By 2030, 50 million diabetes patients are expected to be diagnosed in North America, with an additional 40 million diagnosed in Latin America. Enrolling a mere 1% of these patients into the ALRT program would put ALRT significantly in the black and reflect a return on investment for the company and its investors.
ALRT continues to trade on the public market (OTC: ALRT) and its entire portfolio of Stock Information and SEC Filings are available on its website www.alrt.com.
About MEGACAST
MEGACAST is a 21st Century Digital Branding and Advertising Agency with exclusive expertise in Branding & Design, Content Creation, Viral Marketing and Distribution. In addition to boasting the first Integrated Performance Marketing Strategy all under one roof, the company offers comprehensive Live Streaming capabilities; complete PPV functionality; Digital Marketing, Advertising and Distribution solutions; Web and Mobile Application development, and a combined audience reach of more than 100 million. Businesses spend less, achieve more and save substantial time in the process with the MEGACAST suite of services.
About ALR Technologies Inc.
ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with chronic conditions. ALRT has developed the FDA-cleared and HIPAA compliant Health-e-Connect System that collects data from blood glucose meters and uploads to a secure website. Trained Facilitators use the System to effect efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their quality goals. Currently, the Company is focused on diabetes and will expand its services to cover other chronic conditions anchored on verifiable data. More information about ALR Technologies, Inc. can be found at www.alrt.com.
ALR Technologies is active in providing articles, videos and information on diabetes via social media. ALR Technologies can be found on Facebook
at: https://www.facebook.com/ALRTechnologies and on Twitter
at: https://twitter.com/ALRTechnologies.
ALRT Electronic Press Kit: http://www.glntv.tv/alrt
Forward Looking Statements
This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate", "expect", "anticipate", "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company's quarterly filings with the Securities Exchange.
SOURCE: ALR Technologies Inc.